Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sosei Heptares Earns $2.5M Formosa Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sosei Heptares Earns $2.5M Formosa Milestone

Triggered by FDA approval of clobetasol propionate ophthalmic suspension for post-operative inflammation and pain following ocular surgery.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sosei Group Corp. announced that Formosa Pharmaceuticals, Inc. has received approval from the U.S. FDA for clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. The milestone has triggered a $2.5 million payment to Sosei Heptares from Formosa.
 
APP13007 was originally designed and developed at Activus Pharma Inc., formerly a wholly owned subsidiary of the company. Activus was divested in August 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories, Inc., a manufacturer of Active Pharmaceutical Ingredients (APIs) listed on the Taiwan Stock Exchange.
 
Activus was originally developing APP13007 by applying its APNT (Activus Pure Nanoparticle Technology) to the steroid to create a novel nanoparticle formulation for treating post-operative inflammation of the eye. Since the divestment, Formosa has progressed the development of APP13007 and received FDA approval.
 
Under the terms of the sale to Formosa in 2017, Sosei Heptares is entitled to receive undisclosed milestone payments based on progression of Activus’ pipeline as well as royalties from the commercialization of certain products should they reach the market.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics